PRESS RELEASE EMBARGOED UNTIL 6 PM ET, MON. NOV 28.

NEW SCREENING TEST FOR EARLY CANCER DETECTION UNVEILED

TORONTO: Dr. Elaine Chin and Metabolistics Inc. are pleased to announce a breakthrough urine test to screen for breast and ovarian cancer. Dr. Chin’s executive health centre, Scienta Health, is the first in North America to offer this simple, painless and affordable alternative.

The MetaHealthZone™ test from Edmonton health information company, Metabolistics Inc., uses an advanced method of measuring metabolites in an individual’s urine and comparing them to metabolic profiles of disease. Essentially, it’s a chemical signature for breast and ovarian cancer, explains Dr. Chin, that allows for early detection, which is crucial for successful treatment.

“This unique signature gives us even more critical information, quickly and accurately,” adds Dr. Chin, “so we can help our clients take even greater control of their health. We’re excited to be helping our patients with it, and Dr. Slupsky [of Metabolistics Inc] and I believe all women should know it exists, especially now given the new Breast Cancer Screening guidelines.”

Clinical studies show the test has unparalleled accuracy with a sensitivity of 98% and a specificity of 99%. It measures up to 100 different metabolites in an individual's urine to create a “metabolite profile”, which are then compared to clinically validated metabolite profiles of disease, such as breast and ovarian cancers. The MetaHealthZone™ test is the result of years of research by Dr. Carolyn Slupsky, a PhD biochemist who has worked in the field of metabolomics since 2002, and has more than 22 years of experience in biochemistry.

Cancer screening available with no waiting
“We’re working with Dr. Chin to raise awareness of this revolutionary test,” says Dr. Slupsky. “With the controversy over breast cancer screening, we felt compelled to make women aware of this significant and important Made-in-Canada test.

For more information or for an interview, contact:
Dr. Elaine Chin, Scienta Health, 416 222 5880 elaine.chin@scientahealth.com
Dr. Carolyn Slupsky, Director, Metabolistics Inc., 530-426-8332 (California)

About Dr. Elaine Chin,
Dr. Elaine Chin, M.D., M.B.A, is a pioneer in developing an individualized preventive healthcare model. She focuses on leading edge scientific diagnostics and genetic testing combined with a holistic approach to health and wellness management. Dr. Chin has been watching progress in the field of metabolomics for some time and is pleased to share the news about the MetaHealthZone™ test from Metabolistics Inc. Dr. Chin is a founder of one of Toronto’s leading executive health practices helping patients optimize health to achieve peak performance.

Metabolistics Inc. is an Edmonton-based health information company offering an innovative and painless way to detect disease early, which is crucial for the successful treatment of many diseases. To learn more, please email: info@metabolistics.com (separate release attached).
PRESS RELEASE EMBARGOED UNTIL 6 PM ET, MON. NOV 28.

NEW SCREENING TEST DETECTS CANCER WITH EASE AND ACCURACY

Edmonton, Alberta: Health information company, Metabolistics Inc, announces that a urine test for breast and ovarian cancer is now available. This test offers an innovative, painless and affordable way to test for breast and ovarian cancers.

Cancer screening available now with no waiting
Not only is this screening test confidential and painless, but it allows for early detection, which is crucial for successful cancer treatment. There is no need to wait to find a lump or to worry about strange new pains.

The MetaHealthZone™ test measures up to 100 different metabolites in an individual's urine to create a “metabolite profile”. The metabolite profile is compared to clinically validated metabolite profiles of disease such as breast and ovarian cancers. Clinical studies show the test has unparalleled accuracy with a sensitivity of 98% and a specificity of 99%.

“We have been working with Dr. Elaine Chin to raise awareness of this revolutionary test,” says Metabolistics Director Carolyn Slupsky. “With the controversy over breast cancer screening, we felt compelled to provide more women with this significant and important Made-in-Canada test. They need to know there are accurate alternatives. With this screening test as part of a regular health care routine, cancer can be caught early, and lives will be saved.”

“It’s a chemical signature for breast and ovarian cancer,” adds Dr. Chin, “and this unique signature gives us even more critical information, quickly and accurately, so we can help our clients take more control of their health. We’re the first executive health centre to be using it in North America.”

Detecting other cancers
Similar tests will soon be offered by Metabolistics for early detection of colorectal, prostate and lung cancers. This innovative testing method is based on years of research by Dr. Carolyn Slupsky, a PhD biochemist with more than 22 years of experience in biochemistry. Dr. Slupsky has worked in the field of metabolomics since 2002. Dr. Slupsky says, "I'm thrilled that I can use my work in this exciting field to help save lives."

How it works:
Patients request the test from their doctor. Once their urine specimen is screened, they and their doctor receive a MetaHealthZone™ report that presents an analysis of their urine profile, comparing it to that of healthy people and to known profiles for breast or ovarian cancer. Clients can then discuss these results with their doctor. Elizabeth, a client in Edmonton, says, "The test was so simple, and I loved how I could do it on my own time."

For more information or for an interview, contact:
Dr. Elaine Chin, Scienta Health, 416 222 5880 (Toronto)
Carolyn Slupsky, Director, Metabolistics Inc., 530-426-8332 (California)
Steven Slupsky, Director, Metabolistics Inc., 780-993-3866 (Edmonton)

Please note this release is embargoed until 6 pmET, Monday, November 28.

See next page for more information about Metabolistics and Dr. Elaine Chin >>>
About Metabolistics

Metabolistics Inc. is a health information company offering an innovative and painless way to detect disease early, which is crucial for the successful treatment of many diseases. Their personalized health reports through the patented evidence-based MetaHealthZone™ technology compares an individual’s urine metabolite profile with scientifically determined and clinically validated disease profiles. This research has found ways to reveal the links between the products identified in urine and a person’s health status. Metabolistics, an Edmonton-based company, was chosen to pilot the new Government of Alberta International Innovation Vouchers Program. For more information, email: info@metabolistics.com

About Dr. Elaine Chin, M.D., M.B.A
Dr. Elaine Chin is a pioneer in developing an individualized preventive healthcare model. She focuses on leading edge scientific diagnostics and genetic testing combined with a holistic approach to health and wellness management. Dr. Chin is a founder of one of Toronto’s leading executive health practices focusing on peak performance through an integrative science based approach to maintaining optimal health. To reach Dr. Chin, email elaine.chin@scientahealth.com